Supriya Lifescience Ltd

Supriya Lifescience Ltd has issued an email communication to its shareholders detailing the dividend taxation provisions as per the Income Tax Act, 1961. The company will deduct tax at source (TDS) on the recommended final dividend of Re. 1.00 per equity share for FY 2025-26, subject to shareholder approval. The TDS rates will vary based on the shareholder's residential status and submitted documentation. Resident individual shareholders with aggregate dividend income not exceeding ₹10,000 will be exempt. Shareholders are urged to update their details with the RTA for accurate tax deduction.

Supriya Lifescience Ltd has announced the closure of its trading window for all insiders and designated persons, including their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, and will reopen 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. The specific date for the Board Meeting to consider these results will be communicated separately.

Supriya Lifescience Ltd. announced strong financial results for Q4 FY26 and the full year FY26. For Q4 FY26, revenue surged 50.2% year-over-year to ₹276.53 crore, with Profit After Tax (PAT) at ₹74.23 crore. For the full fiscal year FY26, revenue from operations grew 18.9% YoY to ₹827.87 crore, and PAT increased 11.3% YoY to ₹209.12 crore. The anesthetic segment was the primary growth driver, contributing 54% of total revenues in FY26. Europe remained the largest market, and export contribution was strong at approximately 82% of FY26 revenues. The company also commercialized its Liquid Anesthetic product, improved capacity utilization to 74%, and strengthened its manufacturing and R&D infrastructure.

Supriya Lifescience Ltd's Board of Directors, in its meeting held on May 27, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹1.00 per equity share (50% on the face value of ₹2 each), subject to shareholder approval at the upcoming Annual General Meeting. The meeting commenced at 03:45 p.m. and concluded at 06:00 p.m.

Supriya Lifescience Ltd announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results and recommended a final dividend of ₹1.00 per equity share (50% on the face value of ₹2 each), subject to shareholder approval at the upcoming Annual General Meeting. The auditor's report indicated an unmodified opinion on the standalone financial results.

Supriya Lifescience Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. They recommended a final dividend of ₹1.00 per equity share (50% on face value of ₹2), subject to shareholder approval at the upcoming Annual General Meeting. The board meeting commenced at 3:45 p.m. and concluded at 6:00 p.m.

Supriya Lifescience Ltd has scheduled a Board of Directors meeting on May 27, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a dividend, if any, on the equity shares of the company for the financial year ended March 31, 2026. The trading window for dealing in the company's securities is closed from April 1, 2026, until 48 hours after the declaration of the audited financial results.

Supriya Lifescience Ltd. announced the successful completion of a USFDA inspection at its Lote, Maharashtra manufacturing facility, conducted from February 2 to February 6, 2026. The inspection concluded with a Form 483 containing one minor observation, which the company addressed adequately. The company received an Establishment Inspection Report (EIR) indicating "Voluntary Action Indicated (VAI)", signifying a successful completion of the inspection. The company reaffirms its commitment to maintaining cGMP compliance across all facilities.

Supriya Lifescience Ltd has announced the closure of the trading window for all insiders and designated persons in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the company’s Code of Conduct. The closure is effective from Wednesday, April 01, 2026 until 48 hours after the declaration of the Audited Financial Results for the quarter and year ending on March 31, 2026. The date of the Board Meeting for consideration and declaration of the Audited Financial Results will be intimated in due course.

Supriya Lifescience Ltd has announced the completion of the tenure of two Independent Directors, Mr. Dinesh Navnitlal Modi and Mr. Dileep Kumar Jain. Both directors have completed their five-year consecutive terms. The board has reconstituted its committees in accordance with the SEBI regulations. The company expressed gratitude for the directors' contributions during their long-term association.